Abbott Gains FDA Clearance For Lab-Based Concussion Test
Executive Summary
Abbott said it received the US FDA nod to run its blood-based test to assess patients for concussions on its Alinity i laboratory instrument. This will make the test more widely available in hospitals and laboratories in the US.
You may also be interested in...
News We're Watching: Abbott, Click, Otsuka, Prenosis Win FDA Approval; EU Health Data Space Proposal, And More
This week, Abbott, Click and Otsuka, Prenosis won the FDA nod respectively for an in vitro diagnostic to evaluate patients for concussion, the first prescription digital therapeutic to treat major depressive disorder and a software to predict sepsis. Also on the regulatory front, the FDA will now take 513(g)s forms via its eSTAR framework. In Europe, the debate of what personal information can be shared continues.
CES 2023: Abbott, Seth Rogen, An Avatar For Old Folks, And A Smart Toilet For The Heartbroken
In this first roundup of innovative digital health solutions showcased at CES 2023, Medtech Insight highlights Abbott’s award-winning tech, an AARP-sponsored panel discussion on Alzheimer’s with Seth and Lauren Miller Rogen, Care.coach, and Casana, a smart toilet for monitoring patients with heart disease.
Abbott Collaborates With U.S. Military On Head Injury Diagnostic
The U.S Department of Defense announced a collaboration Abbott to develop portable blood tests to help evaluate potential concussions that will run on for Abbott's i-STAT point-of-care testing system.